Xeris Biopharma Holdings, Inc. (XERS) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
XERS Revenue Growth
Revenue Breakdown (FY 2025)
XERS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
XERS Revenue Analysis (2016–2025)
As of May 8, 2026, Xeris Biopharma Holdings, Inc. (XERS) generated trailing twelve-month (TTM) revenue of $314.9 million, reflecting explosive growth of +38.3% year-over-year. The most recent quarter (Q1 2026) recorded $83.1 million in revenue, down 3.1% sequentially.
Looking at the longer-term picture, XERS's 5-year compound annual growth rate (CAGR) stands at +70.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $291.8 million in 2025, representing a new all-time high.
Revenue diversification analysis shows XERS's business is primarily driven by Product (85%), Keveyis (14%), and Product, Other (1%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including LNTH (+0.6% YoY), SUPN (+16.3% YoY), and PAHC (+32.4% YoY), XERS has outperformed the peer group in terms of revenue growth. Compare XERS vs LNTH →
XERS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| XERSCurrent | $315M | +38.3% | +70.2% | 8.5% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% | |
 CORT | $761M | +12.2% | +16.6% | 5.9% | |
 AMRX | $3.0B | +8.0% | +8.7% | -0.2% |
XERS Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $291.8M | +43.7% | $238.4M | 81.7% | $24.9M | 8.5% |
| 2024 | $203.1M | +23.9% | $166.2M | 81.9% | $-33,646,000 | -16.6% |
| 2023 | $163.9M | +48.7% | $135.3M | 82.5% | $-44,010,000 | -26.8% |
| 2022 | $110.2M | +122.3% | $87.6M | 79.5% | $-81,940,000 | -74.3% |
| 2021 | $49.6M | +142.7% | $36.3M | 73.1% | $-115,156,000 | -232.2% |
| 2020 | $20.4M | +650.7% | $11.1M | 54.4% | $-83,546,000 | -408.8% |
| 2019 | $2.7M | +10.4% | $1.1M | 41.1% | $-122,380,000 | -4496.0% |
| 2018 | $2.5M | +58.4% | $2.4M | 98.3% | $-59,344,000 | -2407.5% |
| 2017 | $1.6M | +44.7% | $1.6M | 99.7% | $-26,629,000 | -1711.4% |
| 2016 | $1.1M | - | $1.1M | 99.3% | $-13,231,000 | -1230.8% |
See XERS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XERS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XERS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXERS — Frequently Asked Questions
Quick answers to the most common questions about buying XERS stock.
Is XERS's revenue growth accelerating or slowing?
XERS revenue is accelerating at +38.3% year-over-year, exceeding the 5-year CAGR of +70.2%. TTM revenue reached $315M. Growth momentum has increased versus prior periods.
What is XERS's long-term revenue growth rate?
Xeris Biopharma Holdings, Inc.'s 5-year revenue CAGR of +70.2% reflects the sustained expansion pattern. Current YoY growth of +38.3% is above this long-term average.
How is XERS's revenue distributed by segment?
XERS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.